tag:blogger.com,1999:blog-2186593343917545414.post2047809379565685751..comments2024-03-10T12:29:30.004-07:00Comments on pediatric neurology: ACTH is more effective than other standard therapies for infantile spasmsGalen Breningstall, MDhttp://www.blogger.com/profile/07170864203251456228noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-2186593343917545414.post-24734348395570697342016-04-01T09:21:08.488-07:002016-04-01T09:21:08.488-07:00At the heart of Valeant's woes is whether or n...At the heart of Valeant's woes is whether or not its business model can be justified by lawmakers. Acquiring and merging is a perfectly acceptable practice in the healthcare sector and other industries. What's being called into question is whether or not drugmakers have the ability/right to drastically increase the prices of acquired drugs without changing the formulations or manufacturing processes. In other words, the value of branded medication is currently on trial, whether you realize it or not.<br /><br />Valeant is certainly not the only company to find itself in the spotlight for its drug-pricing practices. Mallinckrodt(NYSE:MNK) relies heavily on Acthar Gel, an anti-inflammatory medicine acquired when it purchased Questcor Pharmaceuticals for $5.6 billion in 2014. Now priced at about $35,000 per vial, Acthar Gel's price has risen by more than 2,000% since 2005. But in Mallinckrodt's defense, Questcor was responsible for the majority of those price hikes.<br /><br />ttp://www.fool.com/investing/general/2016/03/29/heres-whats-really-at-stake-with-valeant-pharmaceu.aspxGalen Breningstall, MDhttps://www.blogger.com/profile/07170864203251456228noreply@blogger.com